RxDoctor Payments Data

Shariq Ahmad, MD

Nephrology · Layton, UTNPI 1861490211

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.

$763in general payments, 2019–2025

Across 36 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$133
  • Amgen$125
  • AstraZeneca$112
  • Otsuka America Pharmaceutical, Inc.$79
  • Johnson & Johnson$79
  • ANI Pharmaceuticals, Inc.$70
  • plus $164 from 7 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 40th percentile of 74 nephrology providers in Utah.

See all nephrology providers in Utah

Medicare billing

Part B allowed, 2024
$99,088
Medicare patients
279
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol80$73,505
JardianceEmpagliflozin31$49,380
LokelmaSodium Zirconium Cyclosilicate17$13,612
Sevelamer Carbonate25$3,984
Potassium Citrate ErPotassium Citrate36$2,524
Chlorthalidone118$2,153
Calcitriol68$1,541
Losartan Potassium127$1,250
Gentamicin Sulfate15$599
Furosemide102$589
Spironolactone39$500
Calcium Acetate15$464
Nifedipine ErNifedipine20$457
Amlodipine Besylate68$376
Allopurinol25$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$112$87,11797 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 74 nephrology providers in Utah.

Other nephrology in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →